Cesca Therapeutics Inc (NASDAQ: KOOL) is having a great start to the trading session early on this morning, and for good reason. The company announced that its subsidiary has launched a new product, leading to excitement among investors who are sending the stock for the top. Today, we’ll talk about:
- The product launch;
- what we’re seeing from KOOL; and
- what we’ll be watching for ahead.
KOOL Flies On Product Launch
As mentioned above, Cesca Therapeutics is having an incredibly strong start to the trading session this morning after announcing a product launch. in a press release issued early this morning, the company announced that its device subsidiary known as ThermoGenesis® has launched a new product, known as the PXP System. The new product surrounds the rapid processing of autologous bone marrow cells in the point of care setting.
KOOL said that the ThermoGenesis PXP System is an automated, closed system that harvests a preceise volume of cell concentrate from samples of bone marrow aspirate. From there, the product can generate a concentration of bone marrow in less than 20 minutes that comes with consistently high mononuclear cell and CD34+ progenitor cell recovery rates. The system also leads to greater than 98% depletion of contaminating RBCs. From there, processing data is captured using the comapny’s proprietary DataTrak™ software to assist with Good Manufacturing Practice (GMP) process monitoring and reporting information. In a statement, Chris Xu, PhD., CEO at KOOL, had the following to offer:
The commercial launch of our novel PXP System is significant, as it addresses many of the shortcomings of currently-available systems, most notably, red blood cell contamination in the resulting cell concentrate that is thought to diminish the efficacy of cell based treatments… PXP allows clinicians to rapidly achieve very high stem and progenitor cell recovery rates with negligible RBC contamination – typically less than 2% of the starting sample. The on-time commercial launch of PXP serves to further solidify our position as a leading innovator in the field of cellular processing, and together with our CAR-TXpress™ and related X-Series™ systems, comprises what we believe is the most advanced and clinically differentiated portfolio of cellular processing solutions available today.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn when we start to dig into the market is that the news causes moves. In the case of Cesca Therapeutics, the news proved to be overwhelmingly positive. After all, the product launch will likely lead to revenue growth, and that’s just what investors want to see. So, it comes as no surprise that investors are excitedly sending the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:35), KOOL is trading at $0.50 per share after a gain of $0.039 per share or 8.50% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on KOOL. In particular, we’re interested in following the story surrounding the company’s continued work to bring new products to market that will effectively lead to rises in revenue. We’ll also be watching for revenue generated by the newly launched PXP system. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!